194 related articles for article (PubMed ID: 25667432)
1. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
[No Abstract] [Full Text] [Related]
2. [New therapies for rheumatoid arthritis].
Salgado E; Maneiro JR
Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
4. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
5. Biologic agents for rheumatoid arthritis: 2008 and beyond.
Sweiss NJ; Hushaw LL
J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
[TBL] [Abstract][Full Text] [Related]
6. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
9. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab: is there life beyond anti-TNF blockade?
Alves JD; Marinho A; Serra MJ
Int J Clin Pract; 2011 Apr; 65(4):508-13. PubMed ID: 21272164
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response.
Matsuyama Y; Okazaki H; Hoshino M; Onishi S; Kamata Y; Nagatani K; Nagashima T; Iwamoto M; Yoshio T; Ohto-Ozaki H; Tamemoto H; Komine M; Sekiya H; Tominaga S; Minota S
Rheumatol Int; 2012 May; 32(5):1397-401. PubMed ID: 21431944
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R; Ruderman EM
Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
[TBL] [Abstract][Full Text] [Related]
13. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
14. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
Gibbons LJ; Hyrich KL
BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
[TBL] [Abstract][Full Text] [Related]
16. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
[TBL] [Abstract][Full Text] [Related]
17. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.
Hirohata S; Abe A; Murasawa A; Kanamono T; Tomita T; Yoshikawa H
Mod Rheumatol; 2017 Sep; 27(5):766-772. PubMed ID: 27846751
[TBL] [Abstract][Full Text] [Related]
19. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
[TBL] [Abstract][Full Text] [Related]
20. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
